GleamWall
中文EN

LGVN Longeveron Inc.

Pharmaceutical Preparations · Nasdaq · SEC CIK 1721484 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY-18.9%
TTM net income YoY-4.9%
TTM EPS YoY134.5%
Revenue 3-yr CAGR15.0%
Net income 3-yr CAGR—

Margins

Gross margin66.4%
Operating margin-2,020.8%
Net margin-1,921.7%
FCF margin-1,560.1%
EBITDA margin-1,952.1%

Returns

ROE-305.1%
ROA-162.4%
ROIC (approx.)—
Asset turnover0.08x

Leverage & solvency

Liabilities / assets60.8%
Debt / equity0.00x
Current ratio1.25x
Interest coverage—

Cash quality & payout

Operating cash flow / net income0.80x
Accruals ratio-31.8%
Payout ratio—
Capex / revenue14.4%

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31
Income statement
Revenue$1.20M$2.39M
Cost of revenue$396,000$508,000
Gross profit$803,000$1.88M
R&D expense$12.04M$8.14M
SG&A expense$12.05M$10.27M
Operating income-$23.29M-$16.52M
Income tax$0$0
Net income-$22.70M-$15.97M
EBITDA-$22.49M-$15.82M
EPS (basic)-1.29-2.62
EPS (diluted)-1.29-2.62
Weighted avg. shares (diluted)17.58B9.41B
Balance sheet
Cash & equivalents$4.66M$19.23M
Short-term investments—$0
Receivables$104,000$84,000
Current assets$5.45M$19.62M
PP&E, net$1.84M$2.45M
Intangibles$2.29M$2.40M
Total assets$10.26M$25.56M
Current liabilities$4.09M$2.58M
Total liabilities$4.59M$3.67M
Shareholders' equity$5.67M$21.89M
Cash flow statement
Operating cash flow-$18.64M-$13.87M
Capital expenditure$245,000$655,000
Free cash flow-$18.89M-$14.52M
Investing cash flow-$595,000-$640,000
Financing cash flow$4.67M$28.79M
Depreciation & amortization$800,000$700,000
Stock-based compensation$1.68M$2.33M

Free plan shows the latest 2 periods; Pro shows all 6 🔒

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.